Chris Pak
President & Chief Executive Officer Molecular Targeting Technologies
Chris Pak is Chairman and Chief Executive Officer of Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation targeted cancer radiotherapies. With more than 30 years of biotechnology leadership, he previously served as a scientist and director at Centocor, where he led the development of innovative radiopharmaceutical and molecular imaging technologies prior to the company’s acquisition by Johnson & Johnson. Dr. Pak later secured an exclusive commercial license from the U.S. National Institutes of Health (NIH) for the Evans Blue albumin-binding technology, establishing MTTI’s proprietary radiotherapeutic platform. Under his leadership, MTTI has advanced its lead candidate, ¹⁷⁷Lu-EBTATE, through Phase I/II clinical studies, demonstrating encouraging safety and efficacy in 81 patients with neuroendocrine tumors and positioning EBTATE as a promising next-generation peptide receptor radionuclide therapy (PRRT).
Seminars
- Reviewing how quantitative imaging expertise, dosimetry capabilities and radiopharmacy infrastructure influence treatment consistency, patient management and overall clinical trial quality
- Exploring which partners are best equipped to support multicentre TRP studies through reliable isotope handling, standardised imaging workflows and scalable radiopharmaceutical preparation
- Exploring operational, technological and geographic considerations including software integration, site readiness, turnaround speed and regulatory compliance when selecting long-term dosimetry and radiopharmacy collaborators
- Presenting the latest clinical data supporting EBTATE, including encouraging efficacy, safety and durability outcomes as the programme advances towards pivotal Phase III evaluation
- Examining how enhanced tumour retention and albumin-binding technology enables meaningful therapeutic responses with substantially lower administered radioactivity and without amino acid co-infusion
- Comparing the clinical and practical implications of next-generation PRRT against existing treatment paradigms to understand where meaningful differentiation can be achieved
